SCHEMBL5592068

SCHEMBL5592068

COc1ccc(C(Br)Br)cc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.48
SLC6A4 P31645 2/20 0.48
SLC6A3 Q01959 2/20 0.48
ALOX15 P16050 1/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 1/20 0.42
ACHE P22303 1/20 0.40
NQO2 P16083 1/20 0.40
MAPT P10636 2/20 0.39
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
FFAR1 O14842 1/20 0.38
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884192 0.83 PPARG (0.52) ACHEMAPTPPARGPPARDPPARA
SCHEMBL16231322 0.82 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3ALOX15CYP3A4
SCHEMBL13304652 0.81 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3ALOX15CYP3A4
SCHEMBL801219 0.81 HDAC4 (0.48) SLC6A2SLC6A4SLC6A3ACHEMAPT
SCHEMBL16415970 0.80 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3ALOX15CYP3A4
SCHEMBL2160806 0.79 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3ALOX15CYP3A4
SCHEMBL31135381 0.79 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3ALOX15CYP3A4
SCHEMBL13413339 0.79 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3ALOX15CYP3A4
SCHEMBL11347913 0.79 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3ALOX15CYP3A4
SCHEMBL383209 0.78 TAS1R3 (0.42) SLC6A2SLC6A4SLC6A3ALOX15CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007121389-A2 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AS NK-I AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-25 WO disclosed